Association of endothelial dysfunction with cardiovascular risk factors and new‐onset diabetes mellitus in patients with hypertension
- 31 March 2018
- journal article
- research article
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 20 (5) , 935-941
Abstract
Asymmetric dimethylarginine (ADMA), which is the main endogenous inhibitor of nitric oxide synthase, plays a critical role in the process of endothelial dysfunction. The authors evaluated the association between high plasma ADMA levels in patients with hypertension and the presence of cardiovascular risk factors and the development of type 2 diabetes mellitus (DM) and cardiovascular outcomes, including death. The authors evaluated 191 patients with hypertension who were stratified into two groups according to the median value of basal ADMA: those with high levels of plasma ADMA (>0.55 μmol/L) and low levels of plasma ADMA (≤0.55 μmol/L) who were prospectively evaluated over 5.8 years. High ADMA levels were seen in patients with higher weight, body mass index, waist circumference, triglycerides, uric acid, and high‐sensitivity C‐reactive protein, and lower levels of high‐density lipoprotein cholesterol and in patients with type 2 DM. There was an association between high plasma ADMA levels and the occurrence of cardiovascular death. In a subgroup of patients with hypertension free from metabolic syndrome and DM at baseline, there was an association between high ADMA levels and the development of type 2 DM. This study confirms the association of high plasma ADMA levels and the presence of cardiovascular risk factors in patients with hypertension and suggests a positive predictive value of high plasma ADMA levels for cardiovascular death in patients with hypertension and also for the development of type 2 DM in a subgroup of patients with hypertension free from metabolic abnormalities.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo
This publication has 26 references indexed in Scilit:
- Performance of Two Metabolic Syndrome Definitions in the Estimation of Cardiovascular Disease Among Hypertensive PatientsThe Journal of Clinical Hypertension, 2010
- Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsThe Lancet, 2010
- Cellular ADMA: Regulation and actionPharmacological Research, 2009
- Plasma Asymmetric Dimethylarginine and Incidence of Cardiovascular Disease and Death in the CommunityCirculation, 2009
- Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMAVascular Medicine, 2005
- Angiotensin-converting enzyme inhibitors prevent LDL-induced endothelial dysfunction by reduction of asymmetric dimethylarginine levelInternational Journal of Cardiology, 2005
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Cellular and molecular mechanisms of endothelial cell dysfunction.Journal of Clinical Investigation, 1997
- Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failureThe Lancet, 1992
- Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factorNature, 1987